Navigation Links
Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference
Date:2/7/2013

es a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise
'/>"/>

SOURCE Ohr Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and ... entered into non-exclusive Development Agreements with Dexcom, Inc. ... insulin pumps with the Dexcom G5 and G6 ... Tandem,s next generation pump platform with Dexcom,s future ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... HILL, N.C., Feb. 27, 2012  Cempra, Inc. (Nasdaq: ... developing antibiotics to meet critical medical needs in the ... underwriters of its recent initial public offering have exercised ... shares of common stock.  The closing of the over‑allotment ...
... Johnson thought the $912mm charge in the 4th quarter of ... litigation; however the recent 4th quarter charge of $2.9bil partly ... 3 times last year,s amount.  This has ... litigation could top Avandia as the top "class action" litigation ...
Cached Medicine Technology:Cempra, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Cempra, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 3CNJ Enterprises: DePuy ASR Hip Implant Recall Large Contributor to Johnson & Johnson's $2.9 Bil Charge for 4th Quarter 2011 2
(Date:7/31/2015)... ... ... According to the article published July 27 on My News LA, a fire ... by the city’s fire department before it caused major damage throughout the building. The article ... and it was a fire alarm system that tipped off fire fighters so they could ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Well-known for its ... offering wedding cakes with custom designs, making life just a little bit ... designed wedding cakes for each customer who orders one. , The bakery provides a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has proven itself ... various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and ... Botox and fillers. , Staying up to date with the latest cosmetic ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... geared to patients and family members, medical professionals, and researchers, covering a variety ... The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
(Date:7/31/2015)... ... ... Creating one of the most modern fertility centers in the Middle East, ... the boundaries of fertility medicine. , As the leading gynecology and fertility hospital ... affordable treatments, unending hope, and high fertility success rates — all contributing to its ...
Breaking Medicine News(10 mins):Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... as it is commonly known, is generally referred to any ... of an individual. // Stress, as we all know, has ... and the old alike. ,Although it has been ... implications, especially on health, are many. During stress, an important ...
... cancer. According to the statistics it was found that the ... the Brazilian government plans to test the new Gardasil vaccine ... government plans to release the vaccine in the market. Brazilian ... Brazilian women against the human Papilloma virus (HPV). ...
... the combination of HIV and tuberculosis were evidenced from 2003, ... ,Western Cape tops for the highest TB rate in Africa. ... cause of mortality in South Africa. ,Thabo Mbeki, ... the dreaded conditions behind it which put in action after ...
... has ruled that the pharmaceutical companies and the state were ... , and has awarded damages to nine people who had ... were prescribed fibrinogen as well as other coagulants, between 1981 ... that has closed down now. ,The Osaka District ...
... increase rise in the obesity and diabetic rate among ... their life expectancy. //This has also pressurized the already ... from cancer declined about 14 % and also from ... that average life expectancy for Australians, at 78 years ...
... of Abhishek, all of five years and seven months but with ... adult man. ,The boy's face gives the impression of ... have developed like that of an adult. ,Abhishek, ... of Choti Balia, a village in Begusarai district, about 130 km ...
Cached Medicine News:Health News:Doctors Confused by the Manly Characteristics of a Five-year-old Boy 2
... The ABSOLOK EXTRA Ligating Clip Applier ... ligating clips. The instrument and clips are ... of ligation of tubular structures where an ... optimizes visibility of the clip at the ...
... stapler places one staple each time the instrument ... skin and are then formed, thus holding the ... two sizes: wide (having a clip span of ... clip span of 9.9 mm before closure). The ...
The Auto Suture™ SIGNET™ staplers place one staple each time the instrument handles are squeezed. The staples first penetrate the skin and are then formed, thus holding the tissue togethe...
... PREMIUM skin stapler places one ... handle is squeezed. The staple ... is then formed, thus holding ... different sizes of staples, each ...
Medicine Products: